Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma | NEJM
The addition of zolbetuximab, an anti–claudin 18.2 antibody, to chemotherapy in gastric and gastroesophageal junction adenocarcinoma led to longer progression-free and overall survival than chemoth…